%A Wu Xinshu, Zhao Xiaogang, Wu Licun, Cong Bo %T Advances of malignant pleural mesothelioma %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2015.06.017 %P 462-465 %V 42 %N 6 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9674.shtml} %8 2015-06-08 %X Malignant pleural mesothelioma (MPM) is a malignant cancer originated from pleural mesothelial cell. The diagnosis of MPM is based on biopsy of pleura and immunohistochemistry. The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. There are two major surgical procedures: extrapleural pneumonectomy and pleurectomy/decortication. The main of radiotherapy is threedimensional conformal radiotherapy. Cisplatinum combined with pemetrexed is the firstline chemotherapy for the patients with MPM. The principal targets for immunotherapy include regulatory T cells, cytotoxic T lymphocyte associated antigen 4 and PD 1.